Document
IPR2018-00892, No. 1035 Exhibit - Ex 1035 Remingtons (P.T.A.B. Apr. 5, 2018)
Cite Document
IPR2018-00892, No. 1035 Exhibit - Ex 1035 Remingtons (P.T.A.B. Apr. 5, 2018)
+ More Snippets
Document
IPR2018-00892, No. 1010 Exhibit - Ex 1010 Rudnic (P.T.A.B. Apr. 5, 2018)
Cite Document
IPR2018-00892, No. 1010 Exhibit - Ex 1010 Rudnic (P.T.A.B. Apr. 5, 2018)
+ More Snippets
Document
IPR2018-00892, No. 1024 Exhibit - Ex 1024 Yu (P.T.A.B. Apr. 5, 2018)
Cite Document
IPR2018-00892, No. 1024 Exhibit - Ex 1024 Yu (P.T.A.B. Apr. 5, 2018)
+ More Snippets
Document
IPR2018-00892, No. 1020 Exhibit - Ex 1020 Cohen (P.T.A.B. Apr. 5, 2018)
Cite Document
IPR2018-00892, No. 1020 Exhibit - Ex 1020 Cohen (P.T.A.B. Apr. 5, 2018)
+ More Snippets
Document
IPR2018-00892, No. 2006 Exhibit - Larry Husten, Pfizer and Bristol¿¿¿s ARISTOTLE Study Finds the Golden Mean of Anticoagulation (P.T.A.B. Jul. 18, 2018)
Cite Document
IPR2018-00892, No. 2006 Exhibit - Larry Husten, Pfizer and Bristol¿¿¿s ARISTOTLE Study Finds the Golden Mean of Anticoagulation (P.T.A.B. Jul. 18, 2018)
+ More Snippets
Document
IPR2018-00892, No. 2007 Exhibit - Alpesh Amin et al, Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Compared to Warfarin Among Non Valvular Atrial Fibrillation Patients in...
Cite Document
IPR2018-00892, No. 2007 Exhibit - Alpesh Amin et al, Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Compared to Warfarin Among Non Valvular Atrial Fibrillation Patients in the US Me
+ More Snippets
Document
IPR2018-00892, No. 2014 Exhibit - COPEGUS ribavirin Package Insert August 2015 (P.T.A.B. Jul. 18, 2018)
Cite Document
IPR2018-00892, No. 2014 Exhibit - COPEGUS ribavirin Package Insert August 2015 (P.T.A.B. Jul. 18, 2018)
+ More Snippets
Document
IPR2018-00892, No. 2019 Exhibit - Modern Pharmaceutics, Table of Contents Gilbert S Banker Christopher T Rhodes Eds, 4th ed 2002 (P.T.A.B. Jul. 18, 2018)
Cite Document
IPR2018-00892, No. 2019 Exhibit - Modern Pharmaceutics, Table of Contents Gilbert S Banker Christopher T Rhodes Eds, 4th ed 2002 (P.T.A.B. Jul. 18, 2018)
+ More Snippets
Document
IPR2018-00892, No. 1014 Exhibit - Ex 1014 US Patent No 5,314,506 (P.T.A.B. Apr. 5, 2018)
Cite Document
IPR2018-00892, No. 1014 Exhibit - Ex 1014 US Patent No 5,314,506 (P.T.A.B. Apr. 5, 2018)
+ More Snippets
Document
IPR2018-00892, No. 1011 Exhibit - Ex 1011 Stegemann (P.T.A.B. Apr. 5, 2018)
Cite Document
IPR2018-00892, No. 1011 Exhibit - Ex 1011 Stegemann (P.T.A.B. Apr. 5, 2018)
+ More Snippets
Document
IPR2018-00892, No. 1036 Exhibit - Ex 1036 Telephonic Hearing Transcript (P.T.A.B. Sep. 6, 2018)
Cite Document
IPR2018-00892, No. 1036 Exhibit - Ex 1036 Telephonic Hearing Transcript (P.T.A.B. Sep. 6, 2018)
+ More Snippets
Document
IPR2018-00892, No. 2017 Exhibit - ZERIT stavudine Package Insert December 2017 (P.T.A.B. Jul. 18, 2018)
Cite Document
IPR2018-00892, No. 2017 Exhibit - ZERIT stavudine Package Insert December 2017 (P.T.A.B. Jul. 18, 2018)
+ More Snippets
Document
IPR2018-00892, No. 2013 Exhibit - TRENTAL pentoxifylline Package Insert July 2010 (P.T.A.B. Jul. 18, 2018)
Cite Document
IPR2018-00892, No. 2013 Exhibit - TRENTAL pentoxifylline Package Insert July 2010 (P.T.A.B. Jul. 18, 2018)
+ More Snippets
Document
IPR2018-00892, No. 1015 Exhibit - Ex 1015 FDA Guidance Dissolution Testing (P.T.A.B. Apr. 5, 2018)
Cite Document
IPR2018-00892, No. 1015 Exhibit - Ex 1015 FDA Guidance Dissolution Testing (P.T.A.B. Apr. 5, 2018)
+ More Snippets
Document
IPR2018-00892, No. 1032 Exhibit - Ex 1032 Kramer (P.T.A.B. Apr. 5, 2018)
Cite Document
IPR2018-00892, No. 1032 Exhibit - Ex 1032 Kramer (P.T.A.B. Apr. 5, 2018)
+ More Snippets